Back to Search
Start Over
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
- Source :
-
American heart journal [Am Heart J] 2011 Nov; Vol. 162 (5), pp. 900-6. Date of Electronic Publication: 2011 Oct 07. - Publication Year :
- 2011
-
Abstract
- Background: Conventional composite outcomes in heart failure (HF) trials, for example, time to cardiovascular death or first HF hospitalization, have recognized limitations. We propose an alternative outcome, days alive and out of hospital (DAOH), which incorporates mortality and all hospitalizations into a single measure. A refinement, the patient journey, also uses functional status (New York Heart Association [NYHA] class) measured during follow-up. The CHARM program is used to illustrate the methodology.<br />Methods: CHARM randomized 7,599 patients with symptomatic HF to placebo or candesartan, with median follow-up of 38 months. We related DAOH and percent DAOH (ie, percentage of time spent alive and out of hospital) to treatment using linear regression adjusting for follow-up time.<br />Results: Mean increase in DAOH for patients on candesartan versus placebo was 24.1 days (95% CI 9.8-38.3 days, P < .001). The corresponding mean increase in percent DAOH was 2.0% (95% CI 0.8%-3.1%, P < .001). These findings were dominated by reduced mortality (23 days) but enhanced by reduced time in hospital (1 day). Percent time spent in hospital because of HF was reduced by 0.10% (95% CI 0.04%-0.14%, P < .001). The patient journey analysis showed that patients in the candesartan group spent more follow-up time in NYHA classes I and II and less in NYHA class IV.<br />Conclusions: Days alive and out of hospital, especially percent DAOH, provide a valuable tool for summarizing the overall absolute treatment effect on mortality and morbidity. In future HF trials, percent DAOH can provide a useful alternative perspective on the effects of treatment.<br /> (Copyright © 2011 Mosby, Inc. All rights reserved.)
- Subjects :
- Aged
Biphenyl Compounds
Female
Heart Failure drug therapy
Heart Failure pathology
Humans
Linear Models
Male
Mortality
Randomized Controlled Trials as Topic
Severity of Illness Index
Treatment Outcome
United States
Angiotensin II Type 1 Receptor Blockers administration & dosage
Benzimidazoles administration & dosage
Heart Failure mortality
Hospitalization statistics & numerical data
Models, Statistical
Tetrazoles administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6744
- Volume :
- 162
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- American heart journal
- Publication Type :
- Academic Journal
- Accession number :
- 22093207
- Full Text :
- https://doi.org/10.1016/j.ahj.2011.08.003